Patents by Inventor Michael Gerg

Michael Gerg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10982007
    Abstract: A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: April 20, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Dieter Heindl, Christian Klein, Alfred Mertens, Volker Schmid, Michael Schraeml, Monika Soukupova, Michael Tacke
  • Patent number: 10808038
    Abstract: The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 20, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Birgit Bossenmaier, Richard Buick, Stefan Dengl, Michael Gerg, Carmen Peess, Wolfgang Schaefer, Michael Schraeml, Claudio Sustmann
  • Publication number: 20200207874
    Abstract: Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.
    Type: Application
    Filed: December 5, 2019
    Publication date: July 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael GERG, Dieter HEINDL, Gerhard NIEDERFELLNER, Wolfgang SCHAEFER, Michael SCHRAEML, Michael TACKE
  • Patent number: 10647765
    Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: May 12, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Herbert Andres, David Casagolda Vallribera, Hartmut Duefel, Michael Gerg, Christian Scholz, Michael Schraeml
  • Publication number: 20200141930
    Abstract: The present invention relates to a method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto.
    Type: Application
    Filed: January 6, 2020
    Publication date: May 7, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Schraeml, Markus Roessler, Michael Gerg
  • Publication number: 20200140569
    Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.
    Type: Application
    Filed: January 13, 2020
    Publication date: May 7, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Bernhard Eckert, Michael Gerg, Johann Karl, Martin Kaufmann, Julia Riedlinger, Magdelena Swiatek-de Lange, Lars Hillringhaus, Klaus Hirzel, Marcus-Rene Lisy
  • Patent number: 10626177
    Abstract: The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, David Casagolda Vallribera, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Patent number: 10564151
    Abstract: The present invention relates to a method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: February 18, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Michael Schraeml, Markus Roessler, Michael Gerg
  • Publication number: 20190367601
    Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.
    Type: Application
    Filed: March 16, 2018
    Publication date: December 5, 2019
    Inventors: Herbert ANDRES, David CASAGOLDA VALLRIBERA, Hartmut DUEFEL, Michael GERG, Christian SCHOLZ, Michael SCHRAEML
  • Publication number: 20190324025
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 24, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Dieter Heindl, Lars Hillringhaus, Klaus Hirzel, Caroline Dorothea Hojer, Florian Huber, Hans-Peter Josel, Thomas Meier, Michael Schraeml, Edgar Voss
  • Publication number: 20190324024
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 24, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Klaus Hirzel, Caroline Dorothea Hojer, Erasmus Huber, Hans-Peter Josel, Thomas Meier, Michael Schraeml, Leopold Von Proff
  • Publication number: 20190309091
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Lars Hillringhaus, Klaus Hirzel, Caroline Dorothea Hojer, Hans-Peter Josel, Christoph Seidel, Michael Schraeml, Leopold Von Proff
  • Patent number: 10364290
    Abstract: The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: July 30, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Patent number: 10301383
    Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: May 28, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Hartmut Duefel, Michael Gerg, Frank Kowalewsky, Christian Scholz, Michael Schraemi
  • Patent number: 10179815
    Abstract: The present invention relates to isolated antibodies, or an antigen portions thereof, which bind to human HER3. The novel antibodies are of great utility since they allow for the sensitive and specific detection of human HER3. Detection of human HER3 is, e.g., possible in a tissue sample, even when such tissue sample is a formalin-fixed paraffin embedded tissue (FFPET) sample.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: January 15, 2019
    Assignees: VENTANA MEDICAL SYSTEMS, INC., ROCHE MOLECULAR SYSTEMS, INC.
    Inventors: Monika Soukupova, Michael Schraeml, Birgit Bossenmaier, Patrick C. Roche, Michael Gerg, Sebastian Dziadek
  • Publication number: 20180118837
    Abstract: The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Application
    Filed: August 3, 2017
    Publication date: May 3, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Publication number: 20180100022
    Abstract: The invention relates to anti-HER1 antigen binding proteins, e.g. anti-HER1 antibodies, that bind to the beta-hairpin of HER1, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Application
    Filed: November 21, 2017
    Publication date: April 12, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Michael Gerg, Gerhard Niederfellner, Carmen Peess, Michael Schraeml
  • Patent number: 9938340
    Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: April 10, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Herbert Andres, David Casagolda Vallribera, Hartmut Duefel, Michael Gerg, Christian Scholz, Michael Schraeml
  • Publication number: 20180094062
    Abstract: The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Application
    Filed: August 3, 2017
    Publication date: April 5, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, David Casagolda Vallribera, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Patent number: 9840565
    Abstract: The invention relates to anti-HER1 antigen binding proteins, e.g. anti-HER1 antibodies, that bind to the beta-hairpin of HER1, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: December 12, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Michael Gerg, Gerhard Niederfellner, Carmen Peess, Michael Schraeml